Cargando…

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Rationale: Cancer immunotherapy combining immune checkpoint blockade (ICB) with chemotherapeutic drugs has provided significant clinical advances. However, such combination therapeutic regimen has suffered from severe toxicity of both drugs and low response rate of patients. In this study, we propos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, Yujeong, Shim, Man Kyu, Choi, Jiwoong, Yang, Suah, Kim, Jinseong, Yun, Wan Su, Cho, Hanhee, Park, Jung Yeon, Kim, Yongju, Seong, Joon-Kyung, Kim, Kwangmeyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899589/ https://www.ncbi.nlm.nih.gov/pubmed/35265195 http://dx.doi.org/10.7150/thno.69119

Ejemplares similares

All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
por: Song, Sukyung, et al.
Publicado: (2023)

Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
por: Cho, Hanhee, et al.
Publicado: (2021)

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
por: Cho, Hanhee, et al.
Publicado: (2022)

Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity
por: Shim, Man Kyu, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
por: Kim, Jeongrae, et al.
Publicado: (2022)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
por: Wang, Zhenqing, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
por: Blake, Stephen J. P., et al.
Publicado: (2015)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway
por: Nagato, Toshihiro, et al.
Publicado: (2014)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
por: Wu, Yilun, et al.
Publicado: (2019)

Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
por: Choi, Yongwhan, et al.
Publicado: (2020)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
por: Ge, Yanjun, et al.
Publicado: (2022)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cjdtonrvb29f3blf97n03gm47j